)
Aurobindo Pharma is trading higher by 3% at Rs 747 on the BSE after the drug maker announced that it has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market entecavir tablets, indicated for the treatment of chronic hepatitis B virus infection of the liver.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Baraclude® Tablets, 0.5mg and 1mg, of Bristol-Myers Squibb, Aurobindo Pharma said in a statement.
According to IMS, the product has an estimated market size of US$294 million for the twelve months ended June 2015, the company added.
The stock opened at Rs 740 and touched a high of Rs 750 on the BSE. A combined 1.28 million shares changed hands on the counter on the BSE and NSE till 01:13 PM.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Baraclude® Tablets, 0.5mg and 1mg, of Bristol-Myers Squibb, Aurobindo Pharma said in a statement.
According to IMS, the product has an estimated market size of US$294 million for the twelve months ended June 2015, the company added.
The stock opened at Rs 740 and touched a high of Rs 750 on the BSE. A combined 1.28 million shares changed hands on the counter on the BSE and NSE till 01:13 PM.
